Celladon, a biopharmaceutical company backed by multiple corporates, has increased its latest round to $53m on Tuesday, with additional backing from venture firms MPM Capital and LSP Life Sciences Partners. The company had announced a first close at $43m in February.
Celladon was backed in the round by corporate venturing funds for pharma companies – Pfizer Venture Investments, Novartis Venture Funds, and Johnson & Johnson Development Corporation, as well as life science venture funds Hambrecht & Quist Healthcare/Life Sciences Investors and Lundbeckfond Ventures, and venture capital firms Venrock, Enterprise Partners and GBS Venture Partners.
Celladon has now raised about $109m in equity funding since its inception, together with about $7.3m in debt financing between 2009 and 2011. Additional investors include venture capital firms Kleiner Perkins Caufield & Byers and Domain Associates.